1. Introduction {#sec1-ijms-20-06232}
===============

Monoamine oxidase (MAO) is a flavoenzyme in the outer mitochondrial membrane of neuronal and non-neuronal cells that has a vital role in the etiology of age-regulated neurodegenerative disorders (NDs). MAO catalyzes the oxidative deamination of monoamine neurotransmitters, dietary amines, and xenobiotics and regulates their levels and functions in the brain. During oxidative deamination, MAO liberates hydrogen peroxide, the reactive oxygen species (ROS) most potent in causing oxidative stress and mitochondrial dysfunction \[[@B1-ijms-20-06232]\]. Though the etiology of NDs remains unclear, apoptosis, oxidative stress, mitochondrial dysfunction, inflammation, an impaired ubiquitin-proteasome system, and excitotoxicity are common disease-modifying factors \[[@B2-ijms-20-06232]\]. Two isoforms (MAO-A and MAO-B) with specific functions have been identified in different brain regions and cell types \[[@B3-ijms-20-06232]\].

MAO-A displays a higher affinity for serotonin (5HT) and norepinephrine, whereas MAO-B prefers phenylethylamine. Dopamine (DA) and tyramine are common substrates for both isozymes \[[@B4-ijms-20-06232]\]. MAO-A is associated with the onset of psychiatric disorders ([Figure 1](#ijms-20-06232-f001){ref-type="fig"}), including depression, and antisocial aggressive impulsive behaviors through its ability to decrease neurotransmitter levels (DA and serotonin) \[[@B5-ijms-20-06232],[@B6-ijms-20-06232]\]. During a normal physiological state, DA levels in substantia nigra pars compacta (SNpc) are regulated as an equilibrium between synthesis, synaptic vesicle loading, uptake, and catabolism. MAO enzyme mediates oxidative deamination of DA to DOPAL along with H~2~O~2~ generation, leading DA deficit and oxidative stress state. And MAO-A inhibition prevents the deamination of neurotransmitters, reduces oxidative stress, and increases the availability of neurotransmitters within noradrenergic and serotonergic neurons of the CNS to regulate neuron signaling via their respective receptors \[[@B4-ijms-20-06232],[@B7-ijms-20-06232]\]. Similarly, MAO-B metabolizes DA to DOPAC and catechol-O-methyltransferase (COMT) degrades it to homovanillic acid (HVA) in astrocyte \[[@B8-ijms-20-06232],[@B9-ijms-20-06232]\]. Therefore, MAO inhibitors function as neuroprotective agents against age-related NDs.

The concept of precision medicine relies on protein targeting, and G protein-coupled receptors (GPCRs) are the largest family of target receptors and membrane proteins. At present, 34% of FDA-approved drugs target GPCRs \[[@B10-ijms-20-06232]\]. GPCRs are widely expressed and activated by a broad range of ligands, including neurotransmitters, hormones, and ions, as well as sensory signals \[[@B11-ijms-20-06232]\]. Neurotransmitters bind to their specific receptors at the postsynaptic cleft and trigger or inhibit neuronal functions and signals by regulating the activity of ion channels. In NDs, especially Parkinson's disease (PD), the selective loss of dopaminergic neurons in the SNpc produces DA deficiency, which triggers cell-specific alterations in intrinsic excitability and synaptic plasticity \[[@B12-ijms-20-06232]\]. Therefore, regulating DA levels or DA receptor signaling is a standard approach to PD treatment. Numerous neurotransmitters and their analogs have therapeutic properties, serve as medicaments for various diseases, and have been the subject of extensive pharmacological studies \[[@B13-ijms-20-06232]\]. In this study, we discuss the critical physicochemical interactions between our test ligands and different residue side chains and the adjacent amino acids.

*Morus alba* Linn, commonly known as mulberry, is a perennial woody plant of the family Moraceae that is widely cultivated in tropical, subtropical, and temperate zones in Asia, Europe, and North and South America. The leaves of this plant are used as feed for animals and sericulture, the fruit is used as food, and the wood as timber. Furthermore, in traditional Chinese medicine, the leaves, twigs, fruit, and root bark are used as antioxidant, anti-inflammatory, anti-hypertensive, hypoglycemic, immunomodulatory, hypolipidemic, antibacterial, and anti-tumor agents \[[@B14-ijms-20-06232]\]. The plant thus has unique medicinal and ethnic values. It is rich in flavonoids, alkaloids, steroids, and coumarins. Diels--Alder-type adducts are prototypical metabolites in the root bark \[[@B15-ijms-20-06232]\]. In a previous study, mulberry fruit extract protected dopaminergic neurons in in vitro and in vivo PD models by regulating ROS generation through its antioxidant and anti-apoptotic effects \[[@B16-ijms-20-06232]\]. A crude water extract of *M. alba* leaf ameliorated alterations in the retinal neurotransmitters adrenaline, DA, gamma-aminobutyric acid, histamine, noradrenaline, and serotonin in the pups of diabetic and hypercholesterolemic mother rats \[[@B17-ijms-20-06232]\] and ameliorated kidney damage in diabetic rats by suppressing inflammation and fibrosis via peroxisome proliferator-activated receptor γ (PPARγ) modulation \[[@B18-ijms-20-06232]\]. Similarly, a leaf-ethanol extract possessed anxiolytic and muscle-relaxant activities, probably via a γ-aminobutyric acid A-benzodiazepine (GABA~A~-BZD) mechanism \[[@B19-ijms-20-06232]\]. No previous reports have considered the root bark of *M. alba.* In our recent work, we reported the antidiabetic \[[@B20-ijms-20-06232],[@B21-ijms-20-06232]\], anti-Alzheimer's disease activity \[[@B22-ijms-20-06232],[@B23-ijms-20-06232]\], and antioxidant and anti-browning property \[[@B24-ijms-20-06232]\] of Diels--Alder-type adducts and arylbenzofurans from *M. alba* root bark. More recently, kuwanon G and albanin G from the root bark were hypothesized as the components responsible for the appetite suppression activity of root-bark extract via cannabinoid (CB1) receptor antagonism \[[@B25-ijms-20-06232]\]. In the present study, we characterize the multi-target effects of Diels--Alder-type adducts, mulberrofuran G (**1**), kuwanon G (**2**), and albanol B (**3**) ([Figure 2](#ijms-20-06232-f002){ref-type="fig"}), via human monoamine oxidase (*h*MAO) inhibition and the modulation of dopaminergic receptors (D~1~R, D~2~R, D~3~R, and D~4~R), and we use a molecular simulation to explore the action mechanism of the ligand--receptor interaction.

2. Results {#sec2-ijms-20-06232}
==========

2.1. In Vitro hMAO Inhibition and Enzyme Kinetics {#sec2dot1-ijms-20-06232}
-------------------------------------------------

The in vitro *h*MAO inhibition potentials of **1**--**3** and the reference compound selegiline was evaluated via a chemiluminescent assay in a white, opaque, 96-well plate using the MAO-Glo kit (Promega, Madison, WI). At first, **1**--**3** were screened for *h*MAO activity at 100 µg/mL and the % inhibition was 93.87%, 99.05%, and 74.85%, respectively. Then the compounds were retested at different micromolar concentrations in triplicates and the 50% inhibitory concentration (IC~50~) values obtained from the log-dose inhibition curve are tabulated in [Table 1](#ijms-20-06232-t001){ref-type="table"}.

As shown there, **1**--**3** displayed mild inhibition of *h*MAO-A activity. Among the test compounds, **1** showed the best inhibition, with an IC~50~ value of 54.79 ± 0.03 µM, followed by **2** (IC~50~: 70.16 ± 2.60 µM) and **3** (IC~50~: 114.31 ± 2.30 µM). The inhibition potentials of **1**--**3** were better against *h*MAO-B, though the pattern of inhibition was similar**: 1** showed moderate inhibition effect, with an IC~50~ value of 18.14 ± 1.06 µM, and compounds **2** and **3** mildly inhibited *h*MAO-B, with IC~50~ values of 57.71 ± 2.12 and 90.59 ± 1.72 µM, respectively. The reference inhibitor selegiline inhibited the activity of isozymes -A and -B at IC~50~ values of 12.51 ± 1.11 and 0.30 ± 0.01 µM, respectively. However, compared to the reference reversible *h*MAO-A inhibitor (harmine, IC~50~: 0.006 µM) \[[@B26-ijms-20-06232]\] and reversible *h*MAO-B inhibitor (safinamide, IC~50~: 0.00512 µM) \[[@B27-ijms-20-06232]\], the potency of **1**‒**3** is significantly weaker.

The enzyme inhibition patterns of compounds at different substrate concentrations in the kinetic study are tabulated in [Table 1](#ijms-20-06232-t001){ref-type="table"} and represented in [Figure 3](#ijms-20-06232-f003){ref-type="fig"} and [Figure 4](#ijms-20-06232-f004){ref-type="fig"}. Compounds **1**--**3** competitively inhibited *h*MAO-A isozyme activity with *K*~i~ values of 26.96 ± 3.98, 28.29 ± 2.02, and 46.93 ± 4.12 µM, respectively ([Table 1](#ijms-20-06232-t001){ref-type="table"} and [Figure 3](#ijms-20-06232-f003){ref-type="fig"}a--c). The Lineweaver--Burk plots (1/*V* vs. 1/\[S\]) for *h*MAO-A isozyme activity ([Figure 3](#ijms-20-06232-f003){ref-type="fig"}d--f) reveal an increase in *K*~m~ with an increase in the concentrations of **1**--**3**, whereas 1/*V*~max~ remained constant. Meanwhile, **1** and **2** were noncompetitive inhibitors (*V*~max~ value decreased in a concentration-dependent manner without changing the *K*~m~ value), and **3** was a mixed type inhibitor (increase in inhibitor concentration increased the *K*~m~ value but decreased the *V*~max~ value) of the *h*MAO-B isozyme ([Figure 4](#ijms-20-06232-f004){ref-type="fig"}c,f). From a Secondary plot (plot not shown here), the binding constants of **3** with a free enzyme (*K*~ic~) and with enzyme-substrate complex (*K*~iu~) identified were 55.19 ± 7.97 and 186.2 ± 10.26 µM, respectively. Likewise, the *K*~i~ value of **1** and **2** for *h*MAO-B inhibition was 17.01 ± 3.31 and 52.09 ± 5.56 µM, respectively.

2.2. In Silico Docking Simulation of hMAO {#sec2dot2-ijms-20-06232}
-----------------------------------------

Computational modeling was performed to obtain insights into the binding affinity between ligands and the enzyme using AutoDock 4.2. To validate the docking result, the reference inhibitor selegiline as well as reversible inhibitor harmine (for *h*MAO-A) and safinamide (for *h*MAO-B) were docked into the active site cavity of the *h*MAO enzyme, and the ligands were re-docked. The results of the simulation study are tabulated in [Table 2](#ijms-20-06232-t002){ref-type="table"} and [Table 3](#ijms-20-06232-t003){ref-type="table"} and represented in [Figure 5](#ijms-20-06232-f005){ref-type="fig"}, [Figure 6](#ijms-20-06232-f006){ref-type="fig"} and [Figure 7](#ijms-20-06232-f007){ref-type="fig"}.

As shown in [Table 2](#ijms-20-06232-t002){ref-type="table"}, the test ligand (**1**--**3**)--*h*MAO-A complexes showed lower binding energies (−6.74 to −9.54 kcal/mol) than the reference ligand selegiline (−6.54 kcal/mol) and harmine (−6.46 kcal/mol). Ligand **1** posed in the active site by interacting with Gly110, Thr336, Ile207, Gly214, and Ser209 via a hydrogen bond ([Figure 5](#ijms-20-06232-f005){ref-type="fig"}). Meanwhile, ligands **2** and **3** shared Met300 and Gly404 as common H-bond interacting residues. Reversible inhibitor harmine interacted with flavin adenine dinucleotide (FAD)600, Ile335, and Tyr444 residues at the active site cavity, which were not observed for test ligand-binding. In the case of *h*MAO-B, ligands **1**--**3** showed high affinity with binding energies (−11.09, −12.65, and −10.05 kcal/mol, respectively) by forming three and five H-bond interactions, respectively ([Figure 6](#ijms-20-06232-f006){ref-type="fig"}). With the lowest binding energy, ligand **1** stably positioned in the *h*MAO-B active site by interacting with His115, Pro476, and Glu483 via H-bonds. Moreover, **1** interacted with peripheral residues, including Phe103, Val106, and Ile477. Interacting residues Val106 and Phe103 were shared by all three ligands as a noncompetitive inhibitor. Ligand **2** shared the most abundant H-bond interaction residues: Pro103, Asn116, Glu483, Phe103, and Thr478. Ligand **3** also showed high affinity via H-bond interactions with Thr195, Pro104, Asn116, Thr478, and Gly193. Selegiline interacted with Ile198 and safinamide with Ile199, Cys172, Tyr326, and Thr201 via H-bonds in the active site of *h*MAO-B ([Figure 7](#ijms-20-06232-f007){ref-type="fig"}).

2.3. Cell-Based Functional GPCR Assays {#sec2dot3-ijms-20-06232}
--------------------------------------

To characterize the possible role of compounds **1**--**3** in neuronal diseases, we first screened their functional activity at 100 µM on DA (D~1~, D~2~, D~3~, D~4~) receptors by measuring their effects on secondary messengers (cAMP modulation or Ca^2+^ ion mobilization) in transfected cell lines expressing human cloned receptors of interest. The data in [Table 4](#ijms-20-06232-t004){ref-type="table"} represent the agonist/antagonist effects of **1**--**3** at 100 µM on the various receptors.

As shown in the table, **1**‒**3** exhibited a full antagonist effect on the D~1~/D~2~ receptors and a full agonist effect on the D~3~/D~4~ receptors. The agonist effects of **1**--**3** at 100 µM on D~3~R/D~4~R were 119.9/86.30, 124.3/90.45, and 102.8/46.10%, respectively. Similarly, at 100 µM, **1**‒**3** inhibited the DA response on D~1~R/D~2L~R by 87.65/101.30, 98.85/99.15, and 67.80/78.55%, respectively. [Figure 8](#ijms-20-06232-f008){ref-type="fig"} shows the concentration-dependent functional effect of **1**--**3** on the DA receptor subtypes with corresponding EC~50~/IC~50~ values.

As shown there, all compounds showed promising antagonist effects on D~1~R/D~2L~R, with IC~50~ values in the range of 2.41‒31.22 µM ([Figure 8](#ijms-20-06232-f008){ref-type="fig"}c,d). The rank order for the antagonist effect was D~2L~R \> D~1~R for **1** and D~1~R \> D~2L~R for **2** and **3**. Compared to **1** and **2**, the dose--response curve for **3** ([Figure 8](#ijms-20-06232-f008){ref-type="fig"}c) looks unusual due to relatively higher standard deviation in response at 50 µM concentration. Similarly, **1**‒**3** showed an agonist effect on D~3~R/D~4~R, with EC~50~ values in the range of 12.63‒21.05 µM ([Figure 8](#ijms-20-06232-f008){ref-type="fig"}a,b), and the rank order for the agonist effect was D~3~R = D~4~R for **1** and **2** and D~3~R \> D~4~R for **3**. These results indicate that compounds **1**--**3** mediate the DA function by acting as D~1~R/D~2L~R antagonists and D~3~R/D~4~R agonists.

2.4. In Silico Docking Simulation of Dopamine Receptors {#sec2dot4-ijms-20-06232}
-------------------------------------------------------

To validate the results of the functional assays and investigate and identify the ligand--receptor interactions for novel lead discovery, we carried out a computational docking simulation using AutoDock 4.2 ([Figure 9](#ijms-20-06232-f009){ref-type="fig"}, [Figure 10](#ijms-20-06232-f010){ref-type="fig"}, [Figure 11](#ijms-20-06232-f011){ref-type="fig"} and [Figure 12](#ijms-20-06232-f012){ref-type="fig"}). Since the effect of **1**‒**3** on DA receptors was promising, a simulation study was carried out on DA receptors. The binding affinities of reference ligands for each receptor were also evaluated to better understand and validate the docking results. The homology model of DA receptor subtype D~1~R was based on the structure of the β2-adrenergic receptor because it has a higher similarity to the DA D1 receptor in the binding site region and sequence identity \[[@B28-ijms-20-06232]\]. Subtypes D~2L~R, D~3~R, and D~4~R were obtained from the protein data bank (PDB) IDs for 6CM4, 3PBL, and 5WIV, respectively. The results of the docking simulation are tabulated in [Table 5](#ijms-20-06232-t005){ref-type="table"}, [Table 6](#ijms-20-06232-t006){ref-type="table"}, [Table 7](#ijms-20-06232-t007){ref-type="table"} and [Table 8](#ijms-20-06232-t008){ref-type="table"} and represented in [Figure 9](#ijms-20-06232-f009){ref-type="fig"}, [Figure 10](#ijms-20-06232-f010){ref-type="fig"}, [Figure 11](#ijms-20-06232-f011){ref-type="fig"} and [Figure 12](#ijms-20-06232-f012){ref-type="fig"}. The dotted colored lines in [Figure 9](#ijms-20-06232-f009){ref-type="fig"}, [Figure 10](#ijms-20-06232-f010){ref-type="fig"}, [Figure 11](#ijms-20-06232-f011){ref-type="fig"} and [Figure 12](#ijms-20-06232-f012){ref-type="fig"} represent specific interactions (green line: H-bond; purple line: π-sigma; pale pink: π-alkyl, alkyl; pink: π-π-T-shaped, π-π stacked; orange: π-anion).

As shown in [Table 5](#ijms-20-06232-t005){ref-type="table"}, the **1**‒D~1~R complex exhibited four strong H-bond interactions with Lys81, Leu291, Ser188, and Asp314 with low binding energy (−9.22 kcal/mol). The ligand **2**‒D~1~R complex (−7.1 kcal/mol) interacted with Ser202 and Asp103 in H-bonds, similar to the reference antagonist SCH-23390 and agonist DA. Ligand **3**, with a binding energy of −9.2 kcal/mol, shared Ser188 and Asp187 with D~1~R via H-bonds.

Furthermore, Asp187, Leu295, Phe306, Pro171, Ala192, and Ala195 were revealed as hydrophobic residues in the ligand **3**‒D~1~R complex ([Figure 9](#ijms-20-06232-f009){ref-type="fig"}). [Figure 10](#ijms-20-06232-f010){ref-type="fig"} provides a close-up view of ligands **1**--**3** binding at the active site of D~2L~R. As shown in [Table 6](#ijms-20-06232-t006){ref-type="table"}, ligands **1**--**3** bound strongly to the active site of D~2L~R with low binding energies (−8.11 to −10.45 kcal/mol). Risperidone and butaclamol are D~2L~R agonist and antagonist and they bound to the active site of the receptor with binding energies −12.7 and −6.9 kcal/mol, respectively, by forming salt-bridge with Asp114.

Though ligands **1**--**3** did not form a salt-bridge with Asp114, they showed H-bond and π-anion interactions with the residue. Furthermore, the number of H-bond interactions was higher for test ligands compared to resperidone and butaclamol.

Specifically, Asp114 was an H-bond and electrostatic residue for both ligands **1** and **3**, indicating high affinity with the receptor, whereas Ile184 was a crucially active residue in the second extracellular loop of D~2L~R, forming a π-alkyl interaction with **2**. Phe189 and Val190 are necessary key residues in antagonist-ligand binding, and they were well observed in the **2**‒D~2L~R and **3**‒D~2L~R complexes.

Among the test ligands, **3** showed the highest affinity (−10.41 kcal/mol) for ligand‒D~3~R interactions ([Table 7](#ijms-20-06232-t007){ref-type="table"}). Ligand **1** had a slightly higher binding energy than **3** but was comparable to that of reference agonist DA (−6.9 kcal/mol).

The key conserved interacting residue, Asp110 in the transmembrane III of D~3~R, could be seen in all three ligands‒D~3~R complexes via electrostatic interaction ([Figure 11](#ijms-20-06232-f011){ref-type="fig"}). Other important residues, such as Phe345 and Tyr365, fit tightly into ligands **1**--**3** via *π-π* hydrophobic bonds. Val111 at helix III was also observed forming a *π*-alkyl interaction with both ligands **1** and **3**. Ligands **1**--**3** also interacted with neighboring residues, including His349, Ile183, Thr369, Val86, and Cys114. Similarly, at D~4~R, all the test ligands showed strong interactions with lower binding energies (−12.42 to −9.67 kcal/mol) than the reference drugs ([Table 8](#ijms-20-06232-t008){ref-type="table"}).

DA, nemonapride, and clozapine were used as the reference agonist and antagonist and had binding energies of −6.1, −13.08, and −10.14 kcal/mol, respectively.

One of the most crucial residues in stimulating D~4~R, Asp115 interacted with all three ligands in *π*-anion form at helix III, whereas Ser197 interacted only with **1** and **3** on in helix V ([Figure 12](#ijms-20-06232-f012){ref-type="fig"}). Ligand **3** showed an H-bond interaction with Asp115 and Ser196, which is probably why it had the lowest binding energy (−12.42 kcal/mol) among the three ligands. Similarly, Val116, His414, and Leu187 were common interaction sites for three ligands at D~4~R. Other surrounding residues, including Met112, Thr434, Arg186, Phe410, Cys119, and Val193, were involved in hydrophobic interactions with the ligands.

3. Discussion {#sec3-ijms-20-06232}
=============

In the present study, we tested Diels--Alder type adducts **1**--**3** from the root bark of *M. alba* and found that they exhibit a mild-to-moderate *h*MAO inhibition effect. The inhibition effect was slightly higher on the *h*MAO-B isozyme (IC~50~: 18.14 to 90.59 µM) than on *h*MAO-A (IC~50~: 54.79 to 114.31 µM). In particular, ligand **1** demonstrated a moderate inhibition effect on the *h*MAO-B isozyme, with an IC~50~ value of 18.14 ± 1.06 µM. Among test compounds **1**--**3**, **1** and **3** are fused benzofurans, and **2** is a mono-isoprenyl substituted flavone. The structural difference between **1** and **3** is the methyl cyclohexene in **1** and methylbenzene in **3**. The methyl cyclohexene group of **1** was involved in specific alkyl interactions with Leu337, Ile335, and Met350 and this moiety is facing toward FAD at the *h*MAO-A active site ([Figure 5](#ijms-20-06232-f005){ref-type="fig"}). However, the methylbenzene of **3** was not involved in any interactions, which explains why **1** had better binding affinity and inhibition potency on *h*MAO-A than **3**. Likewise, in *h*MAO-B inhibition, H-bond interaction of **1** with His115, Pro476, and Glu483 might explain for better binding affinity and activity compared to **3**. In addition, **1** and **2** bound in a similar pose and this might explain the same binding mode for both the ligands. The test ligand activity (*K*~i~ values) did not show a strong correlation with the docking score (binding energies). This variation might be attributed to the physicochemical properties of ligands, especially logP which was predicted high in the range of 6.7 to 7.3 from web-based software PreADMET (v2.0, YONSEI University, Seoul, Korea) (data not reported here). Overall, the results of the *h*MAO inhibition assay reveal that these Diels--Alder type adducts, especially **1**, might have therapeutic value in managing PD. However, this treatment approach is just symptomatic, restoring dopaminergic function in the striatum \[[@B29-ijms-20-06232]\]. Therefore, the discovery of new natural DA agonists is promising.

Depending on their stimulation or inhibition of adenylyl cyclase and modulation of cAMP levels, DA receptors are categorized into two classes: D~1~-like (D~1~R and D~5~R) and D~2~-like (D~2~R, D~3~R, and D~4~R). These DA receptors have specific anatomical distributions and specifically mediate DA action \[[@B30-ijms-20-06232]\]. Several studies have pointed to DA receptor antagonists as a promising approach to managing heroin addiction. For instance, a D~1~R antagonist (SCH 23390) and D~2~R antagonists (haloperidol and raclopride) attenuate heroin-induced reinstatement \[[@B31-ijms-20-06232],[@B32-ijms-20-06232]\], and a D~3~R antagonist (SB-277011A) blocks the acquisition and expression of the conditioned place preference response to heroin \[[@B33-ijms-20-06232]\]. Similarly, a natural alkaloid [l]{.smallcaps}-tetrahydropalmatine is a D~1~R/D~2~R antagonist with an anti-addiction property \[[@B34-ijms-20-06232]\], and govadine (D~1~R/D~2~R antagonist) demonstrated antipsychotic properties in conjunction with pro-cognitive effects in rats \[[@B35-ijms-20-06232]\]. The extent of D~2~R binding affinity and antagonizing ability represent the clinical efficacy of antipsychotic drugs \[[@B36-ijms-20-06232]\]. Previously, a root ethanol extract of *M. alba* mediated skin wound healing by upregulating the mRNA levels of chemokine receptor 4, one of the GPCRs \[[@B37-ijms-20-06232]\]. Other than that, no previous studies have reported on GPCR modulation by an *M. alba* root extract or its metabolites.

To evaluate the functional effects of adducts **1**‒**3** on DA (D~1~, D~2~, D~3~, and D~4~) receptors, we conducted a cell-based GPCR functional assay. As shown in [Figure 8](#ijms-20-06232-f008){ref-type="fig"}c,d, **1**--**3** potently and concentration-dependently inhibited the agonist response of DA at D~1~R and D~2L~R. Even at 25 µM, **1**--**3** inhibited the DA response on D~1~R/D~2L~R by 92.32/97.16, 91.09/33.69, and 66.82/81.11%, respectively. Unlike sigmoidal dose--response curves of **1** and **2** at D~1~R, compound **3** showed an unusual non-sigmoidal curve ([Figure 8](#ijms-20-06232-f008){ref-type="fig"}c). A higher standard deviation in response at 50 µM concentration led to unusual appearance. While self-association into colloidal particles at a higher concentration or multi-target actions \[[@B38-ijms-20-06232],[@B39-ijms-20-06232],[@B40-ijms-20-06232]\] explains the possible reason for the observed non-sigmoidal dose--response curve of the compound **3**. Likewise, in the D~2L~R agonist assay, **2** showed nonspecific interference (NSI) in the assay system. This NSI might be attributed to aggregation/colloid formation or chemical reactivity because these are significant sources of nonspecific bioactivity particularly in high throughput screening (HTS) \[[@B41-ijms-20-06232]\]. NSI by aggregates and colloids is detergent sensitive, so it will be confirmed in the coming report. We compared the binding affinity and interacting residues of test compounds **1**--**3** with those of a reference agonist (DA) and antagonist (SCH 23390) via a molecular docking simulation. As shown in [Table 5](#ijms-20-06232-t005){ref-type="table"} and [Table 6](#ijms-20-06232-t006){ref-type="table"}, **1**--**3** showed a high binding affinity (the binding energies of **1**--**3** were lower than those of the reference drugs at D~1~R and D~2~R, except for risperidone at D~2~R). Test ligands **2** shared common H-bond interaction residues, Asp103 and Ser202 with the reference antagonist (SCH 23390). Furthermore, **1**--**3** displayed additional H-bond interactions with serine residues (Ser107, Ser188, and Ser198) and aspartic acid residues (Asp314 and Asp187). Similarly, at D~2~R, **1**--**3** interacted with the key interacting residues Asp114, Trp100, and Phe389 \[[@B42-ijms-20-06232]\]. All three ligands bound to D~2L~R with high affinity and the binding energy was lower than that of the reference antagonist butaclamol. Interactions with Asp114, Cys118, Phe198, Phe389, Trp386, and Tyr416 were common among the test ligands and butaclamol ([Table 6](#ijms-20-06232-t006){ref-type="table"}). Additional H-bond interactions between Ser197 and **1**, Tyr408 and **2**, and Trp100 and **3** were also observed. Residue Ser197 is a conserved-essential residue within the binding site for binding the D~2~R antagonist risperidone \[[@B43-ijms-20-06232]\], which was also observed for test ligand **2** binding. Tyr408 is located deep in the binding site, whereas Trp100 is at the periphery of the binding site of D~2~R \[[@B44-ijms-20-06232]\], and they were both involved in the binding of test ligands **2** and **3**. According to Salmas et al. \[[@B45-ijms-20-06232]\], Phe389, Phe390, and Trp386 in TM6 are main residues for D~2~R-antagonists. Meanwhile, Phe189, Phe198, and Val190 are necessary as key residues for antagonist ligands binding. Here, Phe389 and Val190 are interacting with ligand **2** whereas Val190 and Phe189 are bound to ligand **3** as hydrophobic bond. Using those findings, we characterized **1**--**3** as D~1~R/D~2L~R antagonists. In a previous study, *M. alba* leaf extract possessed D~2~R-mediated anti-dopaminergic activity, suggesting a possible clinical application for *M. alba* leaves in psychiatric disorders \[[@B46-ijms-20-06232]\]. Our findings suggest that **1**--**3** could have antipsychotic effects.

The test compounds showed an agonist effect on D~3~R and D~4~R. As shown in [Figure 8](#ijms-20-06232-f008){ref-type="fig"}a,b, **1**--**3** showed a potent agonist effect on D~3~R and D~4~R. D~3~R is prominently distributed within the limbic system and mediates the psychiatric manifestation of DA receptor stimulation. Therefore, DA receptor agonists with high affinity for D~3~R have an antidepressant effect \[[@B47-ijms-20-06232]\]. Similarly, Levant et al. suggested that D~3~R-stimulation (rather than D~2~R-stimulation) might mediate the antiparkinsonian effects of DA receptor agonists with a high preference for D~2~R \[[@B48-ijms-20-06232]\]. Rotigotine is an FDA-approved, full DA agonist (rank order: D~3~R \>  D~2L~R  \>  D~1~R  =  D~5~R  \>  D~4.4~R) developed as a transdermal patch for the treatment of PD \[[@B1-ijms-20-06232],[@B49-ijms-20-06232]\].

A previously conducted survey reported that more than 110 patent applications had been submitted concerning selective D~3~R ligands \[[@B50-ijms-20-06232]\]. Unfortunately, none of them has yet received clinical approval due to failures of the pharmacokinetics or safety profiles \[[@B51-ijms-20-06232]\]. Similarly, D~4~R agonism has been implicated in the management of cognitive deficits associated with schizophrenia \[[@B52-ijms-20-06232]\] and attention-deficit/hyperactivity disorder \[[@B53-ijms-20-06232]\] and also to reduce the adverse effects of opioids \[[@B54-ijms-20-06232]\].

The results of the functional assays in this study show that the ligands **1**--**3** have concentration-dependent agonist effects on D~3~R and D~4~R (rank order: D~3~R \> D~4~R). Even at 25 µM, **1**--**3** showed potent agonist responses on DA D~3~R/D~4~R of 71.92/63.00, 64.99/58.66, and 94.93/‒%, respectively. The agonist effect of **3** on D~4~R was mild (% stimulation of agonist response of 44.85% at 100 µM). The antagonist effect on these receptor subtypes was negligible. We also used molecular docking simulations to compare the binding affinity and interacting residues between test compounds **1**--**3** and D~3~R ([Table 7](#ijms-20-06232-t007){ref-type="table"}) with those of a reference agonist DA and antagonists (eticlopride and (+)-butaclamol). Likewise, docking simulations of **1**--**3** and D~4~R was compared with those of reference agonists DA and nemonapride, and an antagonist clozapine ([Table 8](#ijms-20-06232-t008){ref-type="table"}). As tabulated in [Table 7](#ijms-20-06232-t007){ref-type="table"} and [Table 8](#ijms-20-06232-t008){ref-type="table"}, the binding energies of **1**--**3** on D~3~R/D~4~R were comparable to the reference ligands. Interestingly, our prediction demonstrated that they had lower binding energy at D~4~R than at D~3~R. Interaction with Asp110 on D~3~R and Asp115 on D~4~R was in common with the agonist DA. It was reported earlier that a salt-bridge to the carboxylic acid group of the Asp110 on *h*D~3~R and the Asp115 on *h*D~4~R is critical to high-affinity ligand binding to dopaminergic receptors \[[@B55-ijms-20-06232]\]. In this study, though ligands **1**--**3** did not form a salt-bridge with those receptors, they did form strong electrostatic interactions (Pi-Anion). In addition to their electrostatic interactions with Asp115 on D~4~R, **2** and **3** formed H-bond interactions with carboxylic acid group of Asp115.

At a molecular level, D1-like (D~1~ and D~5~) receptor signaling is mediated chiefly by the heterotrimeric G proteins Gα~s/olf~, which cause sequential activation of adenylate cyclase, cyclic AMP-dependent protein kinase, and the protein phosphatase-1 inhibitor DARPP-32 \[[@B56-ijms-20-06232]\]. A recent study showed that hypersensitivity of D~1~R is responsible for [l]{.smallcaps}-DOPA-induced activation of mTORC1 signaling, and D~1~R antagonist (SCH23390) blocked the [l]{.smallcaps}-DOPA-induced phosphorylation of p70 S6 kinase (S6K), ribosomal protein S6, and eukaryotic translation initiation factor 4E (eIF4E)-binding protein 1 (4E-BP1) in 6-OHDA--lesioned mice \[[@B57-ijms-20-06232]\]. Moreover, DA through D~1~R induces ERK stimulation via a cAMP/protein kinase A (PKA)/*Rap1*/*B-Raf*/MAPK/ERK kinase (MEK) pathway and SCH 23,390 completely blocks the p-ERK1/2 levels induced by DA \[[@B58-ijms-20-06232]\].

Likewise, D2-like (D~2~, D~3~, and D~4~) receptor signaling is mediated by the heterotrimeric G proteins Gα~i/o~, which causes inhibition of adenylate cyclase thereby decreasing the phosphorylation of PKA substrates. Binding of DA to DA receptors regulate signaling via cAMP response element-binding protein (CREB), glutamate receptors, GABA receptors, and ion channels (e.g., calcium and potassium) \[[@B59-ijms-20-06232]\]. Previous study reports that stimulation of D2-like receptors decreases PKA-stimulated phosphorylation of DARPP-32 at Thr34 and increases phosphorylation at Thr75 \[[@B60-ijms-20-06232],[@B61-ijms-20-06232]\]. Even though DARPP-32 is an important modulator and/or effector of DA receptors signaling, it is not the only modulator of DA-mediated activities \[[@B62-ijms-20-06232]\]. The test compounds of the present study showed a unique profile, i.e., moderate *h*MAO inhibition with good D~1~R/D~2L~R antagonist and D~3~R/D~4~R agonist effect. So, what could be the underlying mechanism and in vivo effect is very interesting and need to be studied shortly.

4. Materials and Methods {#sec4-ijms-20-06232}
========================

4.1. Chemicals and Reagents {#sec4dot1-ijms-20-06232}
---------------------------

Mulberrofuran G (**1**), kuwanon G (**2**), and albanol B (**3**) were isolated and identified from the root bark of *M.* alba Linn following a method described previously \[[@B63-ijms-20-06232]\]. The purity of these compounds was considered to be \>98% as evidenced by spectral data. A MAO-GloTM assay kit was purchased from Promega (Promega Corporation, Madison, WI, USA). Transfected Chinese hamster ovary (CHO) cells were obtained from Eurofins Scientific (Le Bois I'Eveque, France). Hank's balanced salt solution (HBSS), Dulbecco's modified Eagle medium, and 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) buffer were obtained from Invitrogen (Carlsbad, CA, USA). The *h*MAO isozymes and reference drugs selegiline, DA, serotonin, butaclamol, SCH 23390, clozapine, and (S)-WAY-100635 were purchased from Sigma-Aldrich (St. Louis, MO, USA).

4.2. In Vitro Human MAO Inhibition and Enzyme Kinetics {#sec4dot2-ijms-20-06232}
------------------------------------------------------

The potential of the test compounds for human MAO inhibition was evaluated via a chemiluminescence technique using the MAO-Glo kit (Promega, Madison, WI, USA). Detailed experimental conditions and procedures were reported previously \[[@B64-ijms-20-06232],[@B65-ijms-20-06232]\]. The test compounds were evaluated at a concentration of 6, 30, and 120 µM. Selegiline was used as a positive control. The kinetic analysis of *h*MAO inhibition was analyzed at different concentrations of *h*MAO substrate depending on the isozyme (40, 80, and 160 µM for *h*MAO-A and 4, 8, and 16 µM for *h*MAO-B) following the same method of enzyme inhibition. The concentrations of the test compounds for the kinetic study are presented in [Figure 2](#ijms-20-06232-f002){ref-type="fig"} and [Figure 3](#ijms-20-06232-f003){ref-type="fig"}. Kinetic parameters were analyzed using SigmaPlot (v12.0, SPP Inc., Chicago, IL, USA).

4.3. Cell-Based Functional GPCR Assay {#sec4dot3-ijms-20-06232}
-------------------------------------

Cell-based functional GPCR assays were conducted in CHO cells transfected with a plasmid containing the GPCR gene of interest. The functional activity of the test compounds (agonist or antagonist) was evaluated by measuring their effects on cAMP modulation or Ca^2+^ ion mobilization, depending on the receptor type. All assays were performed at Eurofins Cerep (Le Bois I'Eveque, France) following their in-house protocol, as stated in our previous reports \[[@B66-ijms-20-06232],[@B67-ijms-20-06232],[@B68-ijms-20-06232]\].

4.4. Measurement of cAMP Level {#sec4dot4-ijms-20-06232}
------------------------------

The functional activity of the test compounds on D~1~R, D~3~R, and D~4~R was assessed by evaluating the effect on cAMP modulation. For this, stable transfectants (CHO-D~1~R, CHO-D~3~R, and CHO-D~4~R) were suspended in HBSS (Invitrogen, Carlsbad, CA, USA) containing 20 mM HEPES buffer and 500 μM 3-isobutyl-1-methylxanthine, distributed into microplates (5 × 103 cells/well), and incubated for 30 min at room temperature (RT) in the absence (control) or presence of the test compounds (6.25, 12.5, 25, 50, and 100 μM) or reference agonist (DA). In the D~3~R and D~4~R assays, the adenylyl cyclase activator NKH 477 was added at a final concentration of 1.5 and 0.7 μM and incubated for 30 and 10 min, respectively, at 37 °C. Then, the cells were lysed and a fluorescence acceptor (D2-labeled cAMP) and fluorescence donor (anti-cAMP antibody with europium cryptate) were added. The fluorescence transfer was measured at λex = 337 nm and λem = 620 and 665 nm using a microplate reader (Envision, Perkin Elmer, Waltham, MA, USA) after 60 min of incubation at RT. Agonist effects are expressed as the % of the control response to 10 μM DA for D~1~R and 300 nM DA for D~3~R/D~4~R. Similarly, antagonist effects are expressed as the % inhibition of the control response to DA 300 nM for D1R, 10 nM for D~3~R, and 100 nM for D~4~R. The reference agonist DA and antagonists SCH 23390, (+)-butaclamol, and clozapine were used to validate the study.

4.5. Measurement of Intracellular \[Ca^2+^\] Levels {#sec4dot5-ijms-20-06232}
---------------------------------------------------

The functional activity of the test compounds on D~2~R was tested by fluorimetrically evaluating their effect on cytosolic Ca^2+^ ion mobilization. In brief, CHO-D~2L~R cells were separately suspended in HBSS (Invitrogen, Carlsbad, CA, USA) complemented with 20 mM HEPES buffer and distributed into microplates (1 × 105 cells/well). Then, a fluorescent probe (Fluo8, AAT Bioquest) mixed with probenecid in HBSS (Invitrogen, Carlsbad, CA, USA) supplemented with 20 M HEPES (Invitrogen) (pH 7.4) was added to each well, and the cells were allowed to equilibrate for 60 min at 37 °C. Thereafter, the plates were positioned in a microplate reader (FlipR Tetra, Molecular Device), and compounds **1**--**3** (6.25, 12.5, 25, 50, and 100 μM), reference agonist, or HBSS (basal control) were added. We then measured the fluorescent intensity, which varied in proportion to the free cytosolic Ca^2+^ ion concentration. Agonist effects are expressed as the % of the control response to 10 μM DA. Similarly, antagonist effects are expressed as the % inhibition of the control response to 700 nM DA. Reference agonist (DA) and antagonist (butaclamol) were used to validate the study.

4.6. Homology Modeling {#sec4dot6-ijms-20-06232}
----------------------

The primary sequence of the human DA D~1~ receptor was obtained from UniProt (ID: P21728, DRD1_HUMAN). The β~2~R (β2 adrenergic receptor) has a higher similarity to DA D~1~R in the binding site region and sequence identity \[[@B28-ijms-20-06232]\]. Hence, the model was built on the template of the β~2~R crystal structure from the RCSB protein data bank (PDB) using ID 2RH1 with SWISS-MODEL. Refining the model was conducted using the ModRefiner sever \[[@B69-ijms-20-06232]\].

4.7. In Silico Molecular Docking Simulation {#sec4dot7-ijms-20-06232}
-------------------------------------------

Automated single docking simulations were carried out with AutoDock 4.2 \[[@B70-ijms-20-06232]\]. X-ray crystallographic structures of *h*MAO-A, *h*MAO-B, *h*D~2L~R, *h*D~3~R, and *h*D~4~R were obtained from the PDB with IDs 2BXR, 2BYB, 6CM4, 3PBL, and 5WIV, respectively. The 3D chemical structures of the three test compounds were obtained from PubChem Compound (NCBI, CIDs 196583, 5281667, and 480,819 for compounds **1**--**3**, respectively). The crystal structures of the reference compounds, selegiline, harmine, DA, SCH 23390, risperidone, butaclamol, eticlopride, nemonapride, and clozapine were also obtained from NCBI under CIDs 26758, 5280953, 681, 5018, 5073, 37461, 57267, 156333, and 135398737, respectively. Water and ligand molecules were removed using Discovery Studio (v17.2, Accelrys, San Diego, CA, USA). In the case of the *h*MAO isozymes, the cofactor flavin adenine dinucleotide (FAD) was retained. The Lamarckian genetic algorithm method in AutoDock 4.2 was applied. For the docking calculations, Gasteiger charges were added by default, and all the torsions were allowed to rotate. The grid maps were generated with the AutoGrid program. The docking protocol for rigid and flexible ligand docking consisted of 10 independent genetic algorithms, and other parameters were set using the defaults in the AutoDock Tools. The docking results were visualized using Discovery Studio.

5. Conclusions {#sec5-ijms-20-06232}
==============

This study is the first to report the therapeutic potential of natural Diels--Alder type adducts, mulberrofuran G (**1**), kuwanon G (**2**), and albanol B (**3**) from *M. alba* root bark in neurodegenerative diseases. Our investigations identified **1**--**3** as novel multi-target-directed ligands for the management of neurodegenerative diseases via *h*MAO inhibition and dopaminergic receptor modulation. Specifically, cell-based GPCR functional assays in vector-transfected CHO cells expressing DA receptors characterized **1**‒**3** as potent D~1~R/D~2L~R antagonists and D~3~R/D~4~R agonists. The assay results were further supported by molecular docking studies, which predicted tight binding between the test ligands and the receptors. Overall, the results of this study provide evidence that ligands **1**‒**3** from *M. alba* could be developed into neuronal drugs targeting DA receptors. Further in vivo studies are warranted to fully and precisely characterize the mechanism of action via a signal transduction pathway.
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![(**a--c**) Molecular docking simulation of **1**--**3** with human dopamine D~1~ receptor (*h*D~1~R). (**d--f**) 2D diagram of the ligand binding sites.](ijms-20-06232-g009){#ijms-20-06232-f009}

![(**a--c**) Molecular docking simulation of **1**--**3** with human dopamine D~2L~ receptor (*h*D~2L~R). (**d--f**) 2D diagram of the ligand-binding sites.](ijms-20-06232-g010){#ijms-20-06232-f010}

![(**a--c**) Molecular docking simulation of **1**--**3** with human dopamine D~3~ receptor (*h*D~3~R). (**d--f**) 2D diagram of the ligand-binding sites.](ijms-20-06232-g011){#ijms-20-06232-f011}

![(**a--c**) Molecular docking simulation of **1**--**3** with human dopamine D~4~ receptor (*h*D~4~R). (**d--f**) 2D diagram of the ligand-binding sites.](ijms-20-06232-g012){#ijms-20-06232-f012}

ijms-20-06232-t001_Table 1

###### 

Human monoamine oxidase (*h*MAO) inhibitory potential of compounds from *Morus alba.*

  Compounds          Human Monoamine Oxidase A (*h*MAO-A)                                            
  ------------------ ------------------------------------------ ------------------------------------ ----------------
  **1**              54.79 ± 0.03                               26.96 ± 3.98                         Competitive
  **2**              70.16 ± 2.60                               28.29 ± 2.02                         Competitive
  **3**              114.31 ± 2.30                              46.93 ± 4.12                         Competitive
  Selegiline ^d^     12.51 ± 1.11                               *NT*                                 *NT*
  Harmine ^d,\ e^    0.006 \[[@B26-ijms-20-06232]\]             *NT*                                 *NT*
                     **Human Monoamine Oxidase B (*h*MAO-B)**                                        
  **1**              18.14 ± 1.06                               17.01 ± 3.31                         Noncompetitive
  **2**              57.71 ± 2.12                               52.09 ± 5.56                         Noncompetitive
  **3**              90.59 ± 1.72                               55.19 ± 7.79 ^f^/186.2 ± 10.26 ^g^   Mixed
  Selegiline ^d^     0.30 ± 0.01                                *NT*                                 *NT*
  Safinamide ^d,e^   0.00512 \[[@B27-ijms-20-06232]\]           *NT*                                 *NT*

NT: Not tested. ^a^ The 50% inhibitory concentration (IC~50~) values (μM) were calculated from a log dose-inhibition curve and expressed as the mean ± SD of triplicate experiments. ^b^ The *h*MAO inhibition constant (*K*~i~) was determined using a Dixon plot. ^c^ The *h*MAO inhibition type was determined using Lineweaver--Burk plots and Dixon plots. ^d^ Reference inhibitor. ^e^ Values extracted from the literature. ^f,\ g^ *K*~ic~ and *K*~iu~ values, respectively.

ijms-20-06232-t002_Table 2

###### 

Binding site residues and docking scores of **1**--**3** and reference inhibitors in human monoamine oxidase A (*h*MAO-A) (2BXR) obtained using Autodock 4.2.

  Compound           Binding Energy (kcal/mol) ^a^   H-bond Interacting Residues ^b^                          Hydrophobic Interacting Residues ^b^                                                                                                                                        Electrostatic Interacting Residues ^b^
  ------------------ ------------------------------- -------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------
  **1**              −9.54                           Gly110, Thr336, Ile207, Gly214, Ser209                   Val210 (Pi-Sigma, Pi-Alkyl), Ile325 (Pi-Sigma), Phe208 (Pi-Pi Stacked, Pi-Pi T-Shaped), Ile358 (Alkyl), Leu337 (Alkyl), Ile335 (Alkyl), Met350 (Alkyl), Val93 (Pi-Alkyl),   \-
  **2**              −6.74                           Met300, Leu298, Asp359, Gly404, Cys398, Trp397, Glu400   Ala302 (Pi-Alkyl, Alkyl)                                                                                                                                                    \-
  **3**              −8.62                           Gln296, Ile295, Gly404, Tyr410, Met300, Thr183, Ser184   Pro299, Ala279, Ala302 (Pi-Alkyl)                                                                                                                                           Glu188 (Pi-Anion)
  Selegiline         −6.54                           \-                                                       Ile335 (Pi-Sigma), Leu337 (Pi-Alkyl), FAD600 (Pi-Alkyl), Tyr407 (Pi-Alkyl), Tyr444 (Pi-Alkyl)                                                                               \-
  HRM ^c^(Harmine)   −6.46                           FAD600                                                   Tyr444 (Pi-Sigma), FAD600 (Pi-Sigma, Pi-Pi T-shaped, Pi-Alkyl), Tyr444 (Pi-Pi Stacked), Phe352 (Pi-Pi T-shaped), Tyr407 (Pi-Alkyl), Ile335 (Pi-Alkyl)                       \-

^a^ Estimated binding free energy of the ligand--receptor complex. ^b^ The number of hydrogen bonds and all amino acid residues from the enzyme--inhibitor complex was determined with the AutoDock 4.2 program. ^c^ 7-Methoxy-1-methyl-9H-pyrido \[3,4-b\]indole.

ijms-20-06232-t003_Table 3

###### 

Binding site residues and docking scores of **1**--**3** and reference inhibitors in human monoamine oxidase B (*h*MAO-B) (2BYB) obtained using Autodock 4.2.

  Compound         Binding Energy (kcal/mol) ^a^   H-bond Interacting Residues ^b^          Hydrophobic Interacting Residues ^b^                                                                                                                                        Electrostatic Interacting Residues ^b^
  ---------------- ------------------------------- ---------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------
  **1**            −11.09                          His115, Pro476, Glu483                   Phe103 (Pi-Pi Stacked, Pi-Pi T-shaped, Pi-Alkyl), Val106 (Pi-Alkyl), Ile477 (Pi-Alkyl)                                                                                      Glu483(Pi-Anion)
  **2**            −12.65                          Pro104, Asn116, Glu483, Phe103, Thr478   Tyr112 (Pi-Sigma), Phe103 (Pi-Pi Stacked), Val106 (Alkyl, Pi-Alkyl), Pro102 (Alkyl, Pi-Alkyl), Tyr112 (Pi-Alkyl), Trp119 (Pi-Alkyl), Pro104 (Pi-Alkyl), Leu164 (Pi-Alkyl)   Glu483(Pi-Anion)
  **3**            −10.05                          Thr195, Pro104, Asn116, Thr478, Gly193   Ile477 (Pi-Sigma), Trp119 (Pi-Pi Stacked), Phe103 (Pi-Pi T-shaped), Thr195 (Amide-Pi Stacked), Gly194 (Amide-Pi Stacked), Arg120 (Alkyl, Pi-Alkyl), Val106 (Pi-Alkyl)       Asp123(Pi-Anion), Glu483(Pi-Anion)
  Selegiline ^c^   −7.06                           Ile198                                   Tyr398 (Pi-Pi Stacked), Tyr435 (Pi-Pi Stacked), FAD600 (Pi-Pi T-shaped), Leu171 (Alkyl), Cys172 (Alkyl), Phe188 (Pi-Alkyl)                                                  \-
  Safinamide ^c^   −9.86                           Cys172, Ile199, Tyr326, Thr201           Leu171 (Pi-Sigma, Pi-Alkyl), Tyr398 (Pi-Pi Stacked), Tyr326 (Pi-Pi T-shaped), Ile199 (Pi-Alkyl)                                                                             \-

^a^ Estimated binding free energy of the ligand--receptor complex. ^b^ The number of hydrogen bonds and all amino acid residues from the enzyme--inhibitor complex were determined with the AutoDock 4.2 program. ^c^ Reference inhibitors.

ijms-20-06232-t004_Table 4

###### 

Efficacy values (% stimulation and % inhibition) of Diels--Alder type adducts (**1**--**3**) from *M. alba* on DA (D~1~, D~2L~, D~3~, and D~4~) receptors.

  ---------------------------------------------------------------------------------
  Receptors   1                 2                3                Reference Drugs
  ----------- ----------------- ---------------- ---------------- -----------------
  D~1~ (h)    17.2 ± 8.4\       0.85 ± 0.24\     *INTER*\         28\
              (87.65 ± 1.19)    (98.85 ± 1.79)   (67.80 ± 9.05)   (2.8)

  D~2L~ (h)   7.10 ± 1.47\      *NSI*\           4.10 ± 1.06\     12\
              (101.30 ± 0.16)   (99.15 ± 0.77)   (78.55 ± 3.61)   (28)

  D~3~ (h)    119.9 ± 2.44\     124.3 ± 0.76\    102.8 ± 1.36\    4.1\
              (−28.7 ± 11.15)   (−27.4 ± 7.79)   (−13.4 ± 1.87)   (20)

  D~4~ (h)    86.30 ± 0.99\     90.45 ± 0.14\    46.10 ± 1.76\    21\
              (−20.8 ± 6.93)    (−29.6 ± 7.21)   (26.9 ± 5.09)    (150)
  ---------------------------------------------------------------------------------

^a,\ b^ % Stimulation and % inhibition, respectively, of control agonist response at 100 µM of test compounds. ^c^ EC~50~ (nM) values of standard agonist DA. ^d^ IC~50~ (nM) values of standard antagonists (D~1~: SCH-23390, D~2L~: butaclamol, D~3~: (+)-butaclamol, D~4~: clozapine. *INTER*: Test compound interfered with the assay detection method. *NSI*: Test compound interfered nonspecifically in the assay.

ijms-20-06232-t005_Table 5

###### 

Binding sites and docking scores of compounds on *h*D~1~R.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Target          Compounds       Binding Energy (kcal/mol)                       H-bond Interaction Residues                                                                                                                     Hydrophobic Interacting Residues             Electrostatic Interacting Residues
  --------------- --------------- ----------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------- ------------------------------------
  *h*D~1~R        Dopamine ^a^\   −5.59                                           Asp103 (Salt bridge), Ser202, Asn292, Ser199                                                                                                    Phe289 (Pi-Pi T-shaped), Ile104 (Pi-Alkyl)   Phe288(Pi-Cation)
                  (agonist)                                                                                                                                                                                                                                                    

  SCH23390 ^a^\   − 6.94          Asp103 (Salt bridge), Ser199, Ser202            Leu190 (Pi-sigma), Phe288 (Pi-Pi T-shaped), Ile104 (Pi-Alkyl), Ala195 (Pi-Alkyl)                                                                \-                                           
  (antagonist)                                                                                                                                                                                                                                                                 

  **1**           −9.22           Lys81, Leu291, Asp314, Ser188                   Leu295 (Pi-sigma), Phe313 (Pi-Pi Stacked), Phe306 (Pi-Pi T-shaped), Ser188 (Amide-Pi Stacked), Leu295 (Pi-Alkyl), Leu291 (Pi-Alkyl)             Lys81(Pi-Cation), Asp314(Pi-Anion)           

  **2**           −7.1            Lys81, Ser107, Ser202, Asp187, Asp103, Ser198   Val100 (Pi-sigma), Val317 (Pi-Sigma, Pi-Alkyl), Phe313 (Pi-Pi T-shaped), Leu190 (Alkyl), Cys186 (Alkyl), Phe288 (Pi-Alkyl), Ile104 (Pi-Alkyl)   Asp187 (Pi-Anion)                            

  **3**           −9.2            Asp187, Ser188                                  Asp187 (Pi-Sigma). Leu295 (Pi-Sigma, Pi-Alkyl), Phe30 6 (Pi-Pi T-shaped), Pro171 (Pi-Alkyl), Arg192 (Pi-Alkyl), Ala195 (Pi-Alkyl)               \-                                           
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

^a^ Reference ligand for hD~1~R.

ijms-20-06232-t006_Table 6

###### 

Binding sites and docking scores of compounds on *h*D~2L~R.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Target             Compounds       Binding Energy (kcal/mol)        H-bond Interaction Residues                                                                                                                                                                                                     Hydrophobic Interacting Residues             Electrostatic Interacting Residues
  ------------------ --------------- -------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------- ------------------------------------
  *h*D~2L~R          Dopamine ^a^\   −6.98                            Asp114 (Salt bridge), Tyr416, Thr119                                                                                                                                                                                            Trp386 (Pi-Pi T-shaped), Val115 (Pi-Alkyl)   \-
                     (agonist)                                                                                                                                                                                                                                                                                                                     

  Risperidone ^a^\   −12.7           Asp114 (salt bridge), Thr119     Trp100 (Pi-Pi T-shaped, Pi-Alkyl), Trp386 (Pi-Pi T-shaped), Val91(Alkyl), Leu94 (Alkyl), Val115 (Alkyl, Pi-Alkyl), Val111 (Alkyl), Ile184 (Alkyl), Phe110 (Pi-Alkyl), Phe389 (Pi-Alkyl), Cys118 (Pi-Alkyl), Ala122 (Pi-Alkyl)   \-                                           
  (agonist)                                                                                                                                                                                                                                                                                                                                        

  Butaclamol ^a^\    −6.9            Asp114 (Salt bridge), Ser193     Phe389 (Pi-Pi Stacked, Pi-Pi T-shaped, Pi-Alkyl), Tyr416 (Pi-Pi Stacked), Cys118 (Alkyl), Phe198 (Pi-Alkyl), Trp386 (Pi-Alkyl), Phe390 (Pi-Alkyl)                                                                               \-                                           
  (antagonist)                                                                                                                                                                                                                                                                                                                                     

  **1**              −8.11           Ser197, Asp114, Thr412,          Thr412 (Pi-Sigma), Phe110 (Pi-Sigma),\                                                                                                                                                                                          Asp114 (Pi-Anion)                            
                                                                      Trp110 (Pi-Pi T-shaped, Pi-Alkyl), Trp386 (Pi-Pi T-shaped), Tyr416 (Pi-Pi- T-shaped), Val111 (Alkyl), Ile184 (Alkyl),                                                                                                                                                        

  **2**              −8.23           Asn396, Tyr408, Ile184           Tyr408 (Pi-Pi Stacked), Tyr100 (Pi-Pi T-shaped), Phe389 (Pi-Alkyl), Tyr416 (Pi-Alkyl), Ile184 (Pi-Alkyl), Val190 (Pi-Alkyl)                                                                                                     \-                                           

  **3**              −10.45          Trp100, Cys118, Ser193, Asp114   Ile184 (Pi-Sigma, Alkyl), Trp100 (Pi-Pi T-shaped), Trp386 (Pi-Pi T-shaped), Val190 (Alkyl), Phe189 (Pi-Alkyl), Val115 (Pi-Alkyl)                                                                                                Asp114 (Pi-Anion)                            
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

^a^ Reference ligand for *h*D~2L~R.

ijms-20-06232-t007_Table 7

###### 

Binding sites and docking scores of compounds on *h*D~3~R.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Target                Compounds       Binding Energy (kcal/mol)        H-bond Interaction Residues                                                                                                                                                                     Hydrophobic Interacting Residues       Electrostatic Interacting Residues
  --------------------- --------------- -------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------- ------------------------------------
  *h*D~3~R              Dopamine ^a^\   −5.72                            Asp110 (Salt bridge), Tyr373, Val111, Thr115, Ser196                                                                                                                                            Val111 (Pi-Alkyl), Cys114 (Pi-Alkyl)   
                        (agonist)                                                                                                                                                                                                                                                                               

  Eticlopride ^a^\      −9.22           Asp110 (Salt bridge), Tyr373     Phe345 (Pi-Pi T-shaped), Ile183 (Alkyl, Pi-Alkyl), Val189 (Alkyl), VAl111 (Pi-Alkyl)                                                                                                                                                   
  (antagonist)                                                                                                                                                                                                                                                                                                  

  (+)-butaclamol ^a^\   −10.69          Asp110(Salt bridge)              Val111 (Alkyl), Cys114 (Alkyl), Trp342 (Pi-Alkyl), Phe345 (Pi-Alkyl), Phe346 (Pi-Alkyl), Val86 (Pi-Alkyl)                                                                                                                              
  (antagonist)                                                                                                                                                                                                                                                                                                  

  **1**                 −5.89           Tyr365, Cys181, Ser366, Thr369   Ile183 (Pi-Sigma), Phe345 (Pi-Pi T-shaped), His349 (Pi-Pi T-shaped), Tyr365 (Pi-Pi T-shaped), Val86 (Alkyl, Pi-Alkyl), Leu89 (Alkyl), Phe106 (PI-Alkyl), Val107 (Pi-Alkyl), Val111 (Pi-Alkyl)   Asp110 (Pi-Anion)                      

  **2**                 −7.45           Tyr365, Thr369, Cys181,          Thr369 (Pi-Sigma), Phe345(Pi-Pi Stacked, Pi-Alkyl), Phe106 (Pi-Pi T-shaped), Tyr365 (Pi-Pi T-shaped), Val86 (Alkyl), Leu89 (Alkyl), Phe346 (Pi-Alkyl), Val107 (PI-Alkyl)                        Asp110 (Pi-Anion),                     

  **3**                 −10.41          Ile183, Val110, Thr115           Leu89 (Pi-Sigma), Thr359 (Pi-Sigma), Phe345 (Pi-Pi Stacked), Tyr365 (PI-Pi T-shaped), Val86 (Alkyl, Pi-Alkyl), Tyr36 (Pi-Alkyl), Val111 (Pi-Alkyl), Cys114 (Pi-Alkyl),                          Asp110 (Pi-Anion)                      
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

^a^ Reference ligand for *h*D~3~R.
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###### 

Binding sites and docking scores of compounds on *h*D~4~R.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Target             Compounds       Binding Energy (kcal/mol)             H-bond Interaction Residues                                                                                                                                                                                                 Hydrophobic Interacting Residues                             Electrostatic Interacting Residues
  ------------------ --------------- ------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------ ------------------------------------
  *h*D~4~R           Dopamine ^a^\   −6.1                                  Asp115(Salt bridge), Thr120, Ser196, Tyr438                                                                                                                                                                                 Cys119(Pi-Alkyl), Val116(Pi-Alkyl), Phe411(Pi-Pi T-shaped)   
                     (agonist)                                                                                                                                                                                                                                                                                                                                      

  Nemonapride ^a^\   −13.08          Asp115(Salt bridge), Tyr438, Ser196   Val116 (Pi-Sigma), Phe91 (Pi-Pi T-shaped), Phe410 (Pi-Pi T-shaped), Leu90 (Amide-Pi Stacked), Val193 (Alkyl), Leu111 (Pi-Alkyl)                                                                                                                                                          
  (agonist)                                                                                                                                                                                                                                                                                                                                                         

  Clozapine ^a^\     −10.14          Asp115(Salt bridge)                   Leu187(Pi-Sigma), Phe410(Pi-PI T-shaped), His414(Pi-Pi T-shaped), Val116(Alkyl, Pi-Alkyl), Val193(Pi-Alkyl)                                                                                                                                                                              
  (antagonist)                                                                                                                                                                                                                                                                                                                                                      

  **1**              −9.67           Ser196, Leu187, Val430, Thr434        Val116 (Pi-Sigma, Pi-Alkyl), Leu187 (Pi-Sigma), Thr434 (Pi-Sigma), Phe411 (Pi-Pi T-shaped), His414 (PI-Pi T-shaped), Phe410 (Pi-Pi T-shaped), Met112 (Alkyl), Cys185 (Alkyl), Cys119 (Alkyl, Pi-Alkyl), Arg186 (Pi-Alkyl)   Asp115 (Pi-Anion)                                            

  **2**              −10.34          Ser197, Thr434, Asp115, Tyr438        Val193 (Pi-sigma), His414 (Pi-Pi Stacked, Pi-Pi T-shaped), Met112 (Alkyl), Leu187 (Alkyl, Pi-Alkyl), Phe91 (Pi-Alkyl), Arg186 (Pi-Alkyl),Val116 (Pi-Alkyl)                                                                  Asp115 (Pi-Anion)                                            

  **3**              −12.42          Leu187, Asp115, Ser196                Leu187 (Pi-Sigma, Alkyl, Pi-Alkyl), Phe410 (Pi-Pi T-shaped), His414 (Pi-Pi T-shaped, Pi-Alkyl), Val193 (Alkyl, Pi-Alkyl), Val116 (Pi-Alkyl)                                                                                 Asp115 (Pi-Anion)                                            
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

^a^ Reference ligand for *h*D~4~R.

[^1]: These authors contributed equally to this work.
